Capricor Therapeutics Announces Long-Term Benefit Of Deramiocel In Both Skeletal Muscle And Cardiac Function In The HOPE-2 OLE Study In Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) announced positive 3-year safety and efficacy results from its HOPE-2 OLE study for deramiocel (CAP-1002) in treating Duchenne muscular dystrophy. The study showed benefits in both skeletal muscle and cardiac function, with a pre-BLA meeting with the FDA scheduled for Q3 2024.
June 28, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics announced positive 3-year results for its lead asset, deramiocel, in treating Duchenne muscular dystrophy. The study showed benefits in muscle and cardiac function, and a pre-BLA meeting with the FDA is scheduled for Q3 2024.
The positive 3-year results for deramiocel in treating Duchenne muscular dystrophy are likely to boost investor confidence in Capricor Therapeutics. The upcoming pre-BLA meeting with the FDA could expedite the approval process, further enhancing the stock's outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100